High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008)
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The aim of this study is to provide relevant and accurate information on prevalence and treatment patterns of anaemia in Belgian cancer patients.
The Anaemia Day 2008 survey was a single visit, multi-centre, non-interventional study in adult cancer patients under systemic therapy (chemotherapy, hormonal, immunological and/or targeted therapy) and/or radiotherapy. Efforts were made to enrol the maximum number of patients seen in each centre that day. Patients signed an informed consent and relevant data were collected from their files, i.e. disease and disease stage, cancer therapy and anti-anaemic treatment, including transfusions and the use of erythropoietin stimulating agents (ESA). A blood count of each included patient was performed. Haemoglobin (Hb) values (grams per decilitre) were classified into four categories to assess the severity of anaemia, as defined by WHO: no anaemia: Hb ≥ 12 g/dL; mild 10 ≤ Hb ≤ 11.9 g/dL; moderate 8 ≤ Hb ≤ 9.9 g/dL; severe Hb < 8 g/dL. Univariate and multivariate analyses were carried out with anaemia as the dependent variable.
A total of 1,403 eligible patients aged 63 ± 13 years (mean age ± SD) were enrolled in 106 oncology or haematology centres. The mean Hb level (±SD) was 11.6 g/dL (±1.8 g/dL) and the prevalence of anaemia (Hb < 12 g/dL) was 55.7% (95% CI, 53.1–58.3%), respectively, 35.9% mild, 17.8% moderate and 2.1% severe anaemia. Anaemia was more frequent in females than in males, and in patients with haematological malignancies (73.4%) than in those with solid tumours (51.4%; p < 0.001). Anaemia prevalence was higher in hospitalised patients (75.5%) compared to those seen in one-day-clinic (54.3%) or in consultation (33.9%; p < 0.001), and in patients treated with chemotherapy (61.3%) compared to those receiving radiotherapy (34.4%) or hormonal therapy (19.5%; p < 0.001). There was a clear correlation between severity of anaemia and WHO performance status (p < 0.001). Among anaemic patients, 53.1% received no treatment (mean Hb 10.8 ± 0.9 g/dL). Among the anaemic patients who received therapy for their anaemia (mean Hb 9.7 ± 1.1 g/dL), the most frequent treatments were RBC transfusions (42%), ESA (34.6%), transfusions + ESA (12%), ESA + iron (7.9%) and iron alone (3.5%). Comparison to the ECAS survey shows that there has been no major change in attitude towards anaemia management in the last decade.
This survey shows that cancer-related anaemia is still frequently observed in cancer patients. Even if in our study ESA were used more frequently than about 10 years ago, still a large amount of anaemic patients who could be treated for anaemia according to EORTC guidelines, were not.
- Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306 CrossRef
- Caro JJ, Salas M, Ward W et al (2001) Anaemia is an independent prognostic factor for survival in patients with cancer. Cancer 91:2214–2221 CrossRef
- Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating Agents. Oncologist 13:33–36 CrossRef
- Kitano T, Tada H, Nishimura T et al (2007) Prevalence and incidence of anaemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol 86:37–41 CrossRef
- Tas F, Eralp Y, Basaran M et al (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25:371–379 CrossRef
- Seshadri T, Prince HM, Bell DR et al (2005) The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer. Med J Aust 182:453–457
- Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412–3425
- Pelegri A (2007) Impact of erythropoietin treatment on the quality of life of oncologic patients. Clin Transl Oncol 9:645–651 CrossRef
- Glaspy J, Bukowski R, Steinberg D et al (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234
- Bohlius J, Wilson J, Seindenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714 CrossRef
- Bennet CL, Silver S, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anaemia. JAMA 299:914–924 CrossRef
- Henke M, Mattern D, Pepe M et al (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708–4713 CrossRef
- Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality with cancer: a meta-analysis of randomised trials. Lancet 373:1532–1542 CrossRef
- Ludwig H, Aapro M, Bokemeyer C et al (2009) Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 45:1603–1615 CrossRef
- High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008)
Supportive Care in Cancer
Volume 20, Issue 1 , pp 23-28
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Erythropoietin stimulating agents (ESA)
- Industry Sectors
- Author Affiliations
- 1. Department of Medical Oncology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium
- 2. Department of Haematology, University Hospital of Liege, Liege, Belgium
- 3. Department of Oncology, University Hospital of Leuven, Leuven, Belgium
- 4. Department of Haematology–Oncology, Grand Hopital de Charleroi, Charleroi, Belgium
- 5. Department of Haematology, Hospital Virga Jesse of Hasselt, Hasselt, Belgium
- 6. Department of Haematology, UCL Mont-Godinne, Yvoir, Belgium